Colorado is currently home to 1813 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Retina Consultants of Southern CO, Colorado Springs, Colorado
Conditions: Diabetic Macular Edema (DME)
Register for Updates
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Colorado Clinical Research, Aurora, Colorado
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/28/2025
Locations: University of Colorado Anschutz Medical Campus - Department of Family Medicine, Aurora, Colorado
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243
Recruiting
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs). The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data o... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: Asthma and Allergy Associates P C, Colorado Springs, Colorado
Conditions: Chronic Inducible Urticaria
Register for Updates
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
NCT05972629
Recruiting
This is a single group Phase 1/Phase 2, 1-arm, open-label study with SAR444836, an adeno-associated virus (AAV) vector-mediated gene transfer of human phenylalanine hydroxylase (PAH), for the treatment of adult participants with phenylketonuria (PKU) on a chronic, stable diet. The purpose of the study is to evaluate the safety and efficacy of SAR444836 in reducing phenylalanine (Phe) levels and in the elimination of a Phe restricted diet. Participants will receive a one-time intravenous (IV) ad... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/28/2025
Locations: Children's Hospital Colorado - Aurora- Site Number : 8400015, Aurora, Colorado
Conditions: Phenylketonuria
Register for Updates
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
NCT05861999
Recruiting
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered in pediatric participants with SMA and 2 SMN2 copies who previously received onasemnogene abeparvovec and experience a plateau or decline in function. Participants to be enrolled are children \<2 years of age genetically diagnosed with SMA.
Gender:
ALL
Ages:
Between 3 months and 24 months
Trial Updated:
07/28/2025
Locations: Children's Hospital of Colorado, Aurora, Colorado
Conditions: Muscular Atrophy, Spinal
Register for Updates
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153
Recruiting
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/28/2025
Locations: Retina Consultants of Southern Colorado, Colorado Springs, Colorado
Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Register for Updates
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
NCT05730283
Recruiting
The goal of this clinical trial is to test the effectiveness of the study drug, ORC-13361, in preventing hearing loss in patients with NTM infection who are undergoing treatment with IV amikacin therapy. The main question this study aims to answer is: * Is ORC-13661 effective for preventing or lessening hearing loss induced by amikacin treatment? * Is ORC-13661 effective for preventing or lessening other measures of hearing impairment? Participants will be asked to take a study drug while they... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2025
Locations: National Jewish Health, Denver, Colorado
Conditions: Ototoxicity, Drug-Induced
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/28/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Systemic Lupus Erythematosus
Register for Updates
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
NCT05485961
Recruiting
This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: 84000589 - Western Nephrology, Arvada, Colorado
Conditions: Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Register for Updates
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients
NCT05064098
Recruiting
This study will assess how patients' long-term quality of life after different surgical approaches compares to their predicted quality of life.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University of Colorado Hopspital, Aurora, Colorado
Conditions: Breast Cancer
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172
Recruiting
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/28/2025
Locations: St. Mary's Medical Center, Grand Junction, Colorado
Conditions: Intracranial Arteriosclerosis, Stroke
Register for Updates